Rare Gastroenterology News
Spotlight On
Sjögren’s syndrome
Sjögren's syndrome is a long-term autoimmune disease in which the moisture-producing glands of the body are affected
Prevalence
Age of Onset
ICD-10
#N/A
Inheritance
Autosomal dominant
Autosomal recessive
Mitochondrial/Multigenic
X-linked dominant
X-linked recessive
Rare View
Sjögren’s syndrome is a chronic (long-lasting) autoimmune disorder that happens when the immune system attacks the glands that make moisture in the eyes, mouth, and other parts of the body. The main symptoms are dry eyes and mouth, but other parts of the body may be affected as well, with many people reporting fatigue and joint and muscle pain. In addition, the disease can damage the lungs, kidneys, and nervous system. Sjögren’s syndrome predominantly affects women.†
5 Facts you should know
FACT
1
Autoimmune disease that affects the body's moisture-producing glands
FACT
2
The hallmark symptom of Sjögren syndrome is dry mouth and keratoconjunctivitis sicca
FACT
3
Other symptoms can include dry skin, vaginal dryness, a chronic cough, numbness in the arms and legs, feeling tired, muscle and joint pains, and thyroid problems
FACT
4
Vaginal dryness, dry skin, and dry nose may also occur
FACT
5
Those affected are also at an increased risk (15%) of lymphoma
Interest over time
Google searches
Common signs & symptoms
Current treatments
Top Clinical Trials
| Title | Description | Phases | Status | Interventions | Locations | More Information |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome | The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS). The study will enroll 2 SS populations: Population 1 will include participants with moderate to high systemic disease activity defined by European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) >= 5; Population 2 will include participants with moderate to severe subjective symptoms defined by EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score >= 5 and residual stimulated salivary flow but with mild systemic disease activity defined by ESSDAI score < 5. | Phase 2 | Recruiting | Drug: VIB4920|Drug: Placebo | Research Site, Fullerton, California, United States|Research site, Upland, California, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Kansas City, Kansas, United States|Research Site, Baltimore, Maryland, United States| More sites available. Please see the more information link. | More Info |
| A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS) | Phase 2 | Recruiting | Other: Placebo|Drug: Nipocalimab|Drug: Standard of Care Treatment | Arizona Arthritis and Rheumatology Research, PLLC, Glendale, Arizona, United States|Arizona Arthritis & Rheumatology Research, PLLC, Mesa, Arizona, United States|St. Jude Heritage Medical Group, Fullerton, California, United States|Inland Rheumatology Clinical Trials, Inc., Upland, California, United States|More sites available. Please see the more information link. | More Info | |
| Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren's Syndrome | Phase 2 | Recruiting | Drug: CFZ533|Other: Placebo | Novartis Investigative Site, Duluth, Georgia, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|More sites available. Please see the more information link. | More Info | |
| A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome | Phase 2 | Recruiting | Drug: LOU064|Drug: Placebo | Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, San Antonio, Texas, United States|More sites available. Please see the more information link. | More Info | |
| Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome | Phase 3 | Recruiting | Drug: Tivanisiran sodium ophthalmic solution|Drug: Vehicle ophthalmic solution | Sylentis Investigative Site, Scottsdale, Arizona, United States|Sylentis Investigative Site, Glendale, California, United States|Sylentis Investigative Site, Los Angeles, California, United States|Sylentis Investigative Site, Newport Beach, California, United States|Sylentis Investigative Site, Rancho Cordova, California, United States|More sites available. Please see the more information link. | More Info | |
| Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS) | Phase 2 | Recruiting | Drug: SAR441344|Drug: Placebo | Investigational Site Number :8400005, DeBary, Florida, United States|Investigational Site Number :8400001, Duncansville, Pennsylvania, United States|Investigational Site Number :0320002, Caba, Buenos Aires, Argentina|More sites available. Please see the more information link. | More Info | |
| Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients | Phase 2 | Recruiting | Drug: S95011 concentrate for solution for infusion|Drug: Placebo concentrate for solution for infusion | Attune Health, Beverly Hills, California, United States|RASF, Boca Raton, Florida, United States|Tufts School of Dental Medicine, Boston, Massachusetts, United States|Monash Health, Clayton, Australia|More sites available. Please see the more information link. | More Info | |
| Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis | Phase 2 | Recruiting | Drug: branebrutinib|Drug: abatacept|Drug: branebrutinib placebo | Arizona Arthritis and Rheumatology Research, Phoenix, Arizona, United States|Medvin Clinical Research - Covina Office, Covina, California, United States|TriWest Research Associates, El Cajon, California, United States|Encino Research Center, Encino, California, United States||More sites available. Please see the more information link. | More Info |
Top Treatments in Research
| Agent | Class/Mechanism of Action | Development Status | Company | Company Contact | Clinical Studies | More Information |
|---|---|---|---|---|---|---|
| Dazodalibep (HZN - 4920) | A fusion protein binding CD40L on T cells, blocking their interaction with CD40-expressing B cells. | Phase 2 | Horizon Therapeutics | Study Director 1-866-479-6742 ClinicalTrials@VielaBio.com | More Info | More Info |
† Genetic and Rare Diseases Information Center (GARD) - PO Box 8126, Gaithersburg, MD 20898-8126 https://rarediseases.info.nih.gov
